Home About us Current issue Back issues Submission Instructions Advertise Contact Login   

Search Article 
  
Advanced search 
 
Saudi Journal of Kidney Diseases and Transplantation
Users online: 439 Home Bookmark this page Print this page Email this page Small font sizeDefault font size Increase font size 

CASE REPORT Table of Contents   
Year : 2020  |  Volume : 31  |  Issue : 2  |  Page : 521-523
Successful treatment of a patient with posttransplant IgA nephropathy with targeted release formulation of budesonide


1 Department of Nephrology, Institute of Nephro-urology, Bengaluru, Karnataka, India
2 Department of Nephropathology, Manipal Hospitals, Bengaluru, Karnataka, India

Correspondence Address:
Umesh Lingaraj
Department of Nephrology, Institute of Nephro-urology, Victoria Hospital Campus, Bengaluru - 560 002, Karnataka
India
Login to access the Email id


DOI: 10.4103/1319-2442.284029

PMID: 32394927

Rights and Permissions

Recurrence of glomerulonephritis is the third-leading cause of allograft loss. Graft loss due to IgA nephropathy occurs in 10% at 10-year follow-up. The NEFIGAN trial demonstrated that Target Release Formulation (TRF) of budesonide is a specific treatment for IgA nephropathy targeting intestinal mucosal immunity upstream of disease manifestation with favorable safety profile. We are reporting a case of successful treatment of a patient with posttransplant IgA nephropathy with TRF of budesonide.


[FULL TEXT] [PDF]*
Print this article  Email this article
    

  Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
   Citation Manager
  Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed194    
    Printed0    
    Emailed0    
    PDF Downloaded50    
    Comments [Add]    

Recommend this journal